克拉霉素治疗多发性骨髓瘤的研究进展  

Progress of Research on Clarithromycin for Treatment of Multiple Myeloma——Review

作　　者：裘旭华[1] 翟勇平[1] 

机构地区：[1]南京军区南京总医院血液病科,江苏南京210002

出　　处：《中国实验血液学杂志》2015年第1期246-249,共4页Journal of Experimental Hematology

摘　　要：克拉霉素是新一代14元环大环内酯类抗生素,主要用于抗感染治疗。自1997年以来,多项临床试验结果表明,克拉霉素联合用药能显著提高多发性骨髓瘤患者的反应率,延长患者无进展生存期。这个发现使得克拉霉素在多发性骨髓瘤上的作用受到了重视。它为复发难治型多发性骨髓瘤患者增加了一种新疗法,也为多发性骨髓瘤的治疗提供了一种新思路。但是克拉霉素治疗多发性骨髓瘤的相关机制,目前还不清楚,尚需进一步进行探索研究。本文就克拉霉素治疗多发性骨髓瘤的现状及可能的治疗作用机制作一综述。Clarithromycin is a 14-membered ring macrolide antibiotics that is widely used in the treatment of infectious disease. Several clinical investigations showed that clafithromycin was highly efficient for multiple myeloma in improving response rate and survival when used in combination with the conventional chemotherapy since 1997. This finding highlights the importance of clarithromycin on the treatment of multiple myeloma. It offers a new regimen for the relapsed/refractory multiple myeloma patients, and provids a new thought for the treatment of multiple myeloma. However, its related mechanism is still unclear, and more investigations are needed. This review summerizes the recent research progress of clarithromycin for treatment of multiple myeloma and its potential mechanisms.

关 键 词：克拉霉素 多发性骨髓瘤 免疫调节 自噬 

分 类 号：R733.3[医药卫生—肿瘤]